A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of anti-PD-1
and VEGF bispecific antibody (AK112) combined with PARP inhibitor in patients with recurrent
ovarian cancer.